Opsens appoints Denis Harrington to its Board of Directors

Return to news

Quebec City, Quebec, January 20, 2015 – Opsens Inc. (“Opsens”) (TSXV:OPS) is pleased to announce the
appointment of Mr. Denis Harrington as a Director of the Company.

Denis Harrington owns a management and strategy consulting firm he founded in 2012. Prior to
managing his own company, he worked for several medical companies and, among other things, led BridgePoint Medical, Inc., as Chief Executive Officer, from the development stage through commercialization and to a successful acquisition by Boston Scientific Corporation in October 2012.

He joined Boston Scientific Corporation in 1993 and worked for them for 18 years in various roles of increasing responsibility in the U.S. sales organization. Some of his most impressive achievements included managing over 1,800 people and US$3 billion in revenue as Senior Vice-President Cardiology, Rhythm and Vascular Sales. He also played an integral role in the launch of Boston Scientific’s Taxus Stent platform as Sr. Vice-President Cardiology Sales – driving unprecedented revenue growth for the corporation.

A graduate of the West Point United States Military Academy, he served for five years in the United States Army, attaining the rank of Captain. His service was focused in various leadership capacities including platoon and company leadership roles.

Opsens Appoints Chairman to the Board of Directors

Opsens is also pleased to announce the appointment of Mr. Denis M. Sirois as Chairman of its Board of Directors. Denis Sirois, Vice-President, Investments at Telesystem Ltd., has been sitting on Opsens’ board of Directors since 2006.

Mr. Denis M. Sirois, recently nominated as Chairman of the Board, declared: “The Board of Directors is pleased to welcome Denis Harrington. I want to extend my congratulations and wish him success in his term. His appointment will further enrich Opsens’ level of expertise. ”

About Opsens Inc. (www.opsens.com) or Opsens Medical (opsensmedical.com)
Opsens focuses mainly on two large and growing markets: interventional cardiology with a focus on Fractional Flow Reserve (“FFR”) and the industrial, oil & gas segment. In interventional cardiology, Opsens offers an advanced optical-based pressure guidewire (OptoWire) that aims at improving the clinical outcome of patients with coronary artery disease. In the industrial, oil & gas segment, Opsens develops, manufactures and installs innovative fibre optic sensing solutions for critical applications such as the monitoring of oil wells and other demanding industrial

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


For further information, please contact:
Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996
Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.682.9996

Download the PDF version